Overview

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase I trial is studying the side effects of cellular adoptive immunotherapy in treating patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes that relapsed after donor stem cell transplant.

Phase:

Phase 1

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Treatments:

Aldesleukin
Cytarabine
Etoposide
Mitoxantrone